Synthetic peptides and their use
View Patent ↗The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumors.
1. An isolated peptide comprising at least an amino acid sequence selected from the group consisting of:
(SEQ ID NO: 74)
C-F-L-W-R-R-L-M-R-K-L-R,
(SEQ ID NO: 76)
C-W-L-W-R-R-A-M-R-K-V-W,
(SEQ ID NO: 77)
L-R-L-W-R-R-L-M-R-K-V-W,
(SEQ ID NO: 78)
R-R-L-W-R-R-W-M-R-K-V-L,
(SEQ ID NO: 79)
C-R-L-W-R-R-R-M-R-K-V-W,
(SEQ ID NO: 81)
L-R-L-W-R-R-S-M-R-K-V-W,
(SEQ ID NO: 90)
K-K-L-W-R-R-W-W-R-K-V-L,
(SEQ ID NO: 85)
R-W-C-K-L-W-R-R-L-M-R-K-V-R-R-L,
(SEQ ID NO: 86)
R-W-C-F-L-W-R-R-L-M-R-K-H-R-R-L,
(SEQ ID NO: 87)
W-C-K-L-W-R-R-L-M-R-K-V-R-R,
(SEQ ID NO: 93)
W-R-R-W-L-R-K-S-V-K-R-L,
(SEQ ID NO: 94)
W-C-R-W-L-R-K-M-V-K-A-L, and
(SEQ ID NO: 95)
W-R-R-W-L-R-K-M-V-K-R-L.
2. The isolated peptide according to claim 1 consisting of a peptide selected from the group consisting of:
(SEQ ID NO: 74)
C-F-L-W-R-R-L-M-R-K-L-R,
(SEQ ID NO: 76)
C-W-L-W-R-R-A-M-R-K-V-W,
(SEQ ID NO: 77)
L-R-L-W-R-R-L-M-R-K-V-W,
(SEQ ID NO: 78)
R-R-L-W-R-R-W-M-R-K-V-L,
(SEQ ID NO: 79)
C-R-L-W-R-R-R-M-R-K-V-W,
(SEQ ID NO: 81)
L-R-L-W-R-R-S-M-R-K-V-W,
(SEQ ID NO: 90)
K-K-L-W-R-R-W-W-R-K-V-L,
(SEQ ID NO: 85)
R-W-C-K-L-W-R-R-L-M-R-K-V-R-R-L,
(SEQ ID NO: 86)
R-W-C-F-L-W-R-R-L-M-R-K-H-R-R-L,
(SEQ ID NO: 87)
W-C-K-L-W-R-R-L-M-R-K-V-R-R
(SEQ ID NO: 93)
W-R-R-W-L-R-K-S-V-K-R-L,
(SEQ ID NO: 94)
W-C-R-W-L-R-K-M-V-K-A-L, and
(SEQ ID NO: 95)
W-R-R-W-L-R-K-M-V-K-R-L.
3. The isolated peptide according to claim 1 , further comprising CONH 2 at the carboxy terminal end.
4. The isolated peptide according to claim 1 , further comprising CONH 2 at the carboxy terminal end and CH 3 CONH at the amino terminal end.
5. The isolated peptide according to claim 1 , further comprising CONH 2 at the carboxy terminal end and CH 3 CONH at the amino terminal end, and an acetamidomethyl-cysteine in place of a cysteine residue.
6. A pharmaceutical composition comprising a peptide according to claim 1 , claim 2 , claim 3 , claim 4 , or claim 5 .
7. A method for treating bacterial and fungal infections comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 6 .
8. A method for treating impetigo; infected burn wounds; infected abrasions; infected lacerations; infected excoriations; erysipelas; cellulitis; abscesses; furuncles; carbuncles; infected sutured wounds; infected surgical site infections; secondarily infected dermatoses: atopic dermatitis, psoriasis, and allergic contact dermatitis; infected animal bite wounds and catheter related infections, all of which are caused by bacterial and/or fungal infections, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition according to claim 6 .
9. The method according to claim 7 or claim 8 , wherein said administration is oral administration, systemic administration, parenteral administration, local administration, or topical administration.
10. A food stuff comprising a peptide according to claim 1 , claim 2 , claim 3 , claim 4 , or claim 5 .
11. A medicament comprising the peptide according to claim 1 , claim 2 , claim 3 , claim 4 , or claim 5 .
12. An isolated peptide consisting of the amino acid sequence R-R-L-W-R-R-W-M-R-K-V-L (SEQ ID NO:78).